A Study of SYS6010 in Combination With SYH2051 in Patients With Advanced Colorectal Cancer and Other Gastrointestinal Tumors

NAActive, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 18, 2024

Primary Completion Date

November 1, 2024

Study Completion Date

April 30, 2026

Conditions

Colorectal CancerGastric Cancer (GC)Gastrointestinal Tumors

Interventions

DRUG

SYS6010

Administered via intravenous infusion at the dose of 3.2-4.8 mg/kg

DRUG

SYH2051

Administered via oral at the dose of 40-80 mg

Trial Locations (1)

Fujian Provincial Cancer Hospital, Fuzhou

All Listed Sponsors

lead

Fujian Cancer Hospital

OTHER_GOV